Losartan Potassium Tablets — Class II drug recall D-1050-2019
Ongoing recall by Legacy Pharmaceutical Packaging LLC, reported 2019-03-27, distributed in AR, CA, GA, IN, MD. CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected
| Recall number | D-1050-2019 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Legacy Pharmaceutical Packaging LLC, Earth City, MO, United States |
| Recall initiated | 2019-03-01 |
| Classified | 2019-03-21 |
| Reported by FDA | 2019-03-27 |
| Distributed | AR, CA, GA, IN, MD |
| Quantity | 2,497,856 bottles |
| Reason classes | cgmp, specification failure |
| NDC | 68645-0579-54 |
Product
Losartan Potassium Tablets, USP, 100 mg, 30 tablet bottles, Rx Only, Distributed by: Wal-Mart, Bentonville, AR 72716, Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854, Packaged by: Legacy Pharmaceutical Packaging LLC, Earth City, MO 63045. NDC 68645-579-54
Reason for recall
CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1050-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.